» Articles » PMID: 23369007

Farm-derived Gram-positive Bacterium Staphylococcus Sciuri W620 Prevents Asthma Phenotype in HDM- and OVA-exposed Mice

Overview
Journal Allergy
Date 2013 Feb 2
PMID 23369007
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Farm-derived dust samples have been screened for bacteria with potential allergo-protective properties. Among those was Staphylococcus sciuri W620 (S. sciuri W620), which we tested with regard to its protective capacities in murine models of allergic airway inflammation.

Methods: We employed two protocols of acute airway inflammation in mice administering either ovalbumin (OVA) or house dust mite extract (HDM) for sensitization. Mechanistic studies on the activation of innate immune responses to S. sciuri W620 were carried out using human primary monocytic dendritic cells (moDC) and co-culture with autologous T cells.

Results: The allergo-protective properties of S. sciuri W620 were proven in a T(H)2-driven OVA model as well as in a mixed T(H)1/T(H)2 phenotype HDM model as demonstrated by abrogation of eosinophils and neutrophils in the airways after intranasal treatment. In the HDM model, lymph node cell T(H)1/T(H)2 signature cytokines were decreased in parallel. Studies on human moDC revealed an activation of TLR2 and NOD2 receptors and initiation of DC maturation following incubation with S. sciuri W620. Cytokine expression analyses after exposure to S. sciuri W620 showed a lack of IL-12 production in moDC due to missing transcription of the IL-12p35 mRNA. However, such DC selectively supported T(H)1 cytokine release by co-cultured T cells.

Conclusion And Clinical Relevance: Our proof-of-concept experiments verify the screening system of farm-derived dust samples as suitable to elucidate new candidates for allergo-protection. S. sciuri W620 was shown to possess preventive properties on airway inflammation providing the basis for further mechanistic studies and potential clinical implication.

Citing Articles

Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice.

Meng G, Cui H, Feng C, Guo C, Song L, Duan Z PLoS One. 2025; 20(1):e0317587.

PMID: 39820222 PMC: 11737801. DOI: 10.1371/journal.pone.0317587.


Suppression of Pathological Allergen-Specific B Cells by Protein-Engineered Molecules in a Mouse Model of Chronic House Dust Mite Allergy.

Ralchev N, Bradyanova S, Kerekov N, Tchorbanov A, Mihaylova N Int J Mol Sci. 2025; 25(24.

PMID: 39769423 PMC: 11728213. DOI: 10.3390/ijms252413661.


[The role and its regulatory significance of interleukin-25 in ovalbumin induced atopic dermatitis of mice].

Jin J, Chen X, Zhao Y, Jia J, Zhang J Beijing Da Xue Xue Bao Yi Xue Ban. 2024; 56(5):756-762.

PMID: 39397451 PMC: 11480561.


Development of systemic and mucosal immune responses against gut microbiota in early life and implications for the onset of allergies.

Pirker A, Vogl T Front Allergy. 2024; 5:1439303.

PMID: 39086886 PMC: 11288972. DOI: 10.3389/falgy.2024.1439303.


Microbes little helpers and suppliers for therapeutic asthma approaches.

Reuter S, Raspe J, Taube C Respir Res. 2024; 25(1):29.

PMID: 38218816 PMC: 10787474. DOI: 10.1186/s12931-023-02660-7.